Related references
Note: Only part of the references are listed.Everolimus is a new anti-cancer molecule: Metabolic side effects as lipid disorders and hyperglycemia
L. Morviducci et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
Lingaku Lee et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Everolimus in the management of metastatic neuroendocrine tumours
David L. Chan et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism
Xiu Lv et al.
GENES & DISEASES (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
The hypoxic tumor microenvironment: A driving force for breast cancer progression
Gregg L. Semenza
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
The therapeutic potential of mTOR inhibitors in breast cancer
Linda S. Steelman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Caroline Wigerup et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Hypoxic control of metastasis
Erinn B. Rankin et al.
SCIENCE (2016)
Everolimus for Subependymal Giant Cell Astrocytoma: 5-Year Final Analysis
David N. Franz et al.
ANNALS OF NEUROLOGY (2015)
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors
Timothy J. Hobday et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
HIF-1α pathway: role, regulation and intervention for cancer therapy
Georgina N. Masoud et al.
ACTA PHARMACEUTICA SINICA B (2015)
HIF-1-Mediated Suppression of Acyl-CoA Dehydrogenases and Fatty Acid Oxidation Is Critical for Cancer Progression
De Huang et al.
CELL REPORTS (2014)
Targeting PI3K/Akt/mTOR signaling in cancer
Camillo Porta et al.
FRONTIERS IN ONCOLOGY (2014)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Hypoxia-inducible factor 1: Regulator of mitochondrial metabolism and mediator of ischemic preconditioning
Gregg L. Semenza
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Vanessa P. Houde et al.
DIABETES (2010)
The sweet side of HIF
Volker H. Haase
KIDNEY INTERNATIONAL (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
Sanjiv S. Agarwala et al.
ONCOLOGIST (2010)
HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
Rose Du et al.
CANCER CELL (2008)
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia
Huafeng Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Huafeng Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Nicholas C. Denko
NATURE REVIEWS CANCER (2008)
Evaluation of HIF-1 inhibitors as anticancer agents
Gregg L. Semenza
DRUG DISCOVERY TODAY (2007)
HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity
Huafeng Zhang et al.
CANCER CELL (2007)
HIF-1α induces genetic instability by transcriptionally downregulating MutSα expression
M Koshiji et al.
MOLECULAR CELL (2005)
Oxygen sensing by HIF hydroxylases
CJ Schofield et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
HIF-1 as a target for drug development
A Giaccia et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis:: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
E Laughner et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
